Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain
Year: 2023
Type: article
Study design: Observational Study
Abstract: BACKGROUND AND OBJECTIVE: The treatment of psoriasis should not only focus on skin affectations but also weigh the parameters for health-related quality of life (HRQoL), thereby tackling the concept of cumulative life course impairment (CLCI) and treating the patient from a holistic perspective. The CRYSTAL study aimed to characterize psoriasis with real-word data from Spanish clinical practice in patients with moderate to severe disease who received continuous systemic treatment for at least 24 weeks by using the absolute Psoriasis Area and Severity Index (PASI) score and its correlation to HRQoL. MATERIAL AND METHODS: This was a non-interventional, cross-sectional study conducted in 30 centers in Spain, with 301 patients between the ages of 18 and 75 years. The study collected data regarding current treatment and absolute PASI and their relationship to HRQoL using the Dermatology Life Quality Index (DLQI), to activity impairment using the Work Productivity and Activity Impairment (WPAI) questionnaire, and to treatment satisfaction. RESULTS: The mean (SD) age was 50.5 (12.5) years, with a duration of disease of 14 (14.1) years. The mean (SD) absolute PASI reported was 2.3 (3.5), with 28.7% of patients presenting with PASI from >1 to ≤3 and 22.6% with PASI>3. Higher PASI scores were associated with higher DLQI (p<0.001) and WPAI scores and lower levels of treatment satisfaction (p<0.001). CONCLUSIONS: These data indicate that achieving lower absolute PASI values may correlate not only with better HRQoL but also with better work productivity and treatment satisfaction.
Source: Actas Dermo-Sifiliográficas
Authors: E. Daudén, D. Vidal, A. Romero, M.T. Bordel, R. Rivera, J. Márquez, E. Zamora, L. Martinez, M.J. Ocaña, C. Vila, P. Iribarren, N. Corona, A. Zulaica
Institutions: Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Hospital de Sant Joan Despí Moisès Broggi, Hospital Universitario de Fuenlabrada, Hospital Virgen de la Concha, Hospital Universitario 12 De Octubre, Hospital Universitario de Jerez, Hospital Universitario de Móstoles, Hospital Regional Universitario de Málaga, Hospital San Agustín, Hospital Juan Ramón Jiménez, AbbVie (Spain), University Hospital Complex Of Vigo
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid:
Funder: AbbVie
OpenAlex ID: W4383645775
